Progressive Supranuclear Palsy: A Heterogeneous Degeneration Involving the Brain Stem, Basal Ganglia and Cerebellum With Vertical Gaze and Pseudobulbar Palsy, Nuchal Dystonia and Dementia

By J. Steele, J. Richardson, J. Olszewski. Seminars in neurology, 2014

859 citations recorded by the source corpus.

Subfields: Clinical Biochemistry, Endocrinology, Diabetes and Metabolism, Neurology

View Paper: https://www.semanticscholar.org/paper/fa1ddd5d284fa2e0cd9caad4e479b53563025be2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Clinical Biochemistry

1. Dennis W. Dickson

In Endocrinology, Diabetes and Metabolism

1. Dennis W. Dickson

In Neurology

1. Kailash Bhatia
2. Dennis W. Dickson

Citations in the corpus

• Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria (2017, background): “PSP was first described in 1964 on the basis of a small case series as an adult-onset, rapidly progressive neurodegenerative disease with the leading feature of vertical supranuclear gaze palsy and nerve cell degeneration mainly in the brain stem.(1) Since then, major advances have led PSP to be def”
• Parkinson's disease and parkinsonism: neuropathology. (2012, methodology): “2A inset), whereas a-synuclein immunoreactive inclusions in less vulnerable neuronal populations, such as the amygdala and cortex, are pale staining and poorly circumscribed.”